StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
WHO China Data Likely to Drive View that Gilead (GILD) Remdesivir Isn't Working in Severe Patients - Raymond James
April 23, 2020 2:00 PM
Raymond James analyst Steven Seedhouse weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC
April 23, 2020 1:40 PM
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM
SunTrust Said Need to See Gilead Sciences (GILD) Controlled Data on Remdesivir
April 23, 2020 1:32 PM
Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial
April 23, 2020 1:03 PM
Gilead Sciences (GILD) said post included inappropriate characterization of the study - STAT, citing Spokesperson
April 23, 2020 12:56 PM
Gilead Sciences (GILD) Resumes; Shares Down 2.5%
April 23, 2020 12:53 PM
Gilead Sciences (GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
April 23, 2020 12:51 PM
